Uncategorized
GenSight reports visual acuity gains in phase 1/2 study of GS010 for Leber’s hereditary optic neuropathy
GenSight Biologics reported sustained visual acuity improvement in patients with Leber’s hereditary optic neuropathy who were treated with GS010 in a phase 1/2 clinical trial. GenSight reported each cohort of three patients was given an increasing dose of GS010 through a single intravitreal injection into the eye most severely affected by the disease. At baseline, all eyes had an off-chart median visual acuity, according to a company press release.